Equally important, the risks and types of life-threatening infections that come with myelosuppression were increasingly recognized, leading to the development and better use of more effective antibiotics. Starting in the 1990’s, cytokines, drugs that stimulate bone marrow to produce infection-fighting white blood cells, began to be integrated into cancer treatments, further mitigating the risk of life-threatening infectious complications of care.